Cargando…

表皮生长因子受体基因突变非小细胞肺癌的靶向治疗及其耐药机制

Lung cancer is the sixth leading cause of death worldwide and one of the leading cause of death from malignant tumors. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. Epidermal growth factor receptor (EGFR) gene mutation is a common mutation in NSCLC. For advanced NSCLC pa...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 中国肺癌杂志编辑部 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8976207/
https://www.ncbi.nlm.nih.gov/pubmed/35340161
http://dx.doi.org/10.3779/j.issn.1009-3419.2022.101.05
_version_ 1784680516013785088
collection PubMed
description Lung cancer is the sixth leading cause of death worldwide and one of the leading cause of death from malignant tumors. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. Epidermal growth factor receptor (EGFR) gene mutation is a common mutation in NSCLC. For advanced NSCLC patients with EGFR mutations, EGFR-tyrosine kinase inhibitors (EGFR-TKIs), such as Gefitinib, Afatinib, Oxitinib and other targeted therapies have become the first-line treatment recommended by many guidelines, but many patients develop acquired drug resistance after about 1 year of medication. Patients with drug resistance will have earlier disease progression than patients without drug resistance, which has an important impact on the prognosis of patients. At present, the main treatment for patients with acquired resistance is new target inhibition for resistant mutation. For example, if patients with T790M mutation are resistant to the first or second generation drugs such as Gefitinb and Afatinib, they can be treated with the third generation drugs (Osimertinib or Almonertinib), which can delay the progression of the disease. Therefore, the study of drug resistance mechanism and treatment of drug resistance patients are essential. This paper mainly reviews targeted therapy and drug resistance mechanism of EGFR-mutant NSCLC patients, in order to provide reference for clinical application of EGFR-TKIs.
format Online
Article
Text
id pubmed-8976207
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher 中国肺癌杂志编辑部
record_format MEDLINE/PubMed
spelling pubmed-89762072022-04-19 表皮生长因子受体基因突变非小细胞肺癌的靶向治疗及其耐药机制 Zhongguo Fei Ai Za Zhi 综述 Lung cancer is the sixth leading cause of death worldwide and one of the leading cause of death from malignant tumors. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. Epidermal growth factor receptor (EGFR) gene mutation is a common mutation in NSCLC. For advanced NSCLC patients with EGFR mutations, EGFR-tyrosine kinase inhibitors (EGFR-TKIs), such as Gefitinib, Afatinib, Oxitinib and other targeted therapies have become the first-line treatment recommended by many guidelines, but many patients develop acquired drug resistance after about 1 year of medication. Patients with drug resistance will have earlier disease progression than patients without drug resistance, which has an important impact on the prognosis of patients. At present, the main treatment for patients with acquired resistance is new target inhibition for resistant mutation. For example, if patients with T790M mutation are resistant to the first or second generation drugs such as Gefitinb and Afatinib, they can be treated with the third generation drugs (Osimertinib or Almonertinib), which can delay the progression of the disease. Therefore, the study of drug resistance mechanism and treatment of drug resistance patients are essential. This paper mainly reviews targeted therapy and drug resistance mechanism of EGFR-mutant NSCLC patients, in order to provide reference for clinical application of EGFR-TKIs. 中国肺癌杂志编辑部 2022-03-20 /pmc/articles/PMC8976207/ /pubmed/35340161 http://dx.doi.org/10.3779/j.issn.1009-3419.2022.101.05 Text en 版权所有©《中国肺癌杂志》编辑部2022 https://creativecommons.org/licenses/by/3.0/This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/.
spellingShingle 综述
表皮生长因子受体基因突变非小细胞肺癌的靶向治疗及其耐药机制
title 表皮生长因子受体基因突变非小细胞肺癌的靶向治疗及其耐药机制
title_full 表皮生长因子受体基因突变非小细胞肺癌的靶向治疗及其耐药机制
title_fullStr 表皮生长因子受体基因突变非小细胞肺癌的靶向治疗及其耐药机制
title_full_unstemmed 表皮生长因子受体基因突变非小细胞肺癌的靶向治疗及其耐药机制
title_short 表皮生长因子受体基因突变非小细胞肺癌的靶向治疗及其耐药机制
title_sort 表皮生长因子受体基因突变非小细胞肺癌的靶向治疗及其耐药机制
topic 综述
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8976207/
https://www.ncbi.nlm.nih.gov/pubmed/35340161
http://dx.doi.org/10.3779/j.issn.1009-3419.2022.101.05
work_keys_str_mv AT biǎopíshēngzhǎngyīnzishòutǐjīyīntūbiànfēixiǎoxìbāofèiáidebǎxiàngzhìliáojíqínàiyàojīzhì
AT biǎopíshēngzhǎngyīnzishòutǐjīyīntūbiànfēixiǎoxìbāofèiáidebǎxiàngzhìliáojíqínàiyàojīzhì